Roche Diabetes Care
Roche Diabetes Care is recorded as a service provider in 18 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 18 of 18 trials · Latest update first
Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children and adolescents with overweight or obesity
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg once weekly versus placebo in participants with type 2 diabetes as add on to once-daily basal insulin with or without metformin
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- The study was conducted in China, Japan, Serbia, Slovakia, South Africa, and the United States of America.
These findings describe the trial, not the service provider’s performance or responsibility.
Protocol Title: Efficacy and safety of once-weekly subcutaneous NNC0662-0419 in participants with type 2 diabetes – a dose-finding study
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with obesity (AMAZE 1)
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of once-weekly subcutaneous UBT251 in participants with type 2 diabetes – a dose-finding study
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure (AMAZE 3)
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure (AMAZE 4)
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of NNC0487-0111 s.c. once weekly in participants with obesity who have reached target dose during run-in period (AMAZE 12)
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8)
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 2)
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 6)
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 5)
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination with Insulin Aspart, in Adults with Type 1 Diabetes
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A 40-week study comparing the efficacy and safety of once weekly IcoSema and daily insulin glargine 100 units/mL in participants with type 2 diabetes inadequately controlled on oral anti diabetic drugs. COMBINE 4
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec when Switching from Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults with Type 2 Diabetes
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A single arm study investigating the glycaemic control and safety of adding semaglutide to insulin icodec in participants with type 2 diabetes qualifying for treatment intensification.
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A 40-week study comparing the efficacy, safety and patient-reported outcomes of once weekly IcoSema and once or twice daily insulin degludec/insulin aspart 100 units/mL, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily pre-mixed insulin. COMBINE 5
Sponsor Novo Nordisk A/S
- Start (EU)
- Not reported
- Latest update
- Estimated end
Efficacy and safety of once-weekly semaglutide s.c. 2.0 mg as add-on to dose-reduced insulin glargine vs titrated insuline glargine in participants with type 2 diabetes and overweight
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Roche Diabetes Care?
The 2026-10-09 snapshot links Roche Diabetes Care to 18 distinct CTIS trials. Recorded services include Blood Glucose Meter, BG meter supplier, BG Meter, BG meter supplier:, among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Roche Diabetes Care?
The most frequently recorded therapeutic areas are Endocrinology, Metabolic Disorders, Respiratory. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Roche Diabetes Care conducted?
The linked trials record locations in 18 countries, including Poland, Spain, Germany, Italy, Slovakia. These are trial locations, not confirmed office locations or countries where Roche Diabetes Care delivered services.
What can this page tell me about Roche Diabetes Care's trial experience?
Browse 18 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Roche Diabetes Care. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Roche Diabetes Care Inc.